Showing results (61-70 of 626) with videos related to

Sort By:
Pageof 63
Critical Reviews in Oncology/Hematology|September 28, 2013
Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancerPierre-Emmanuel Colombo, Michel Fabbro, Charles Theillet, et al.
The Oncologist|September 19, 2020
Pregnancy in Women with Metastatic SarcomasAlexandre Yazigi, Estelle Lecointe-Artzner, Axel Le Cesne, et al.
Bulletin Du Cancer|July 15, 2003
[Anemia and chemotherapy]Isabelle Ray-Coquard, Thomas Bachelot, Catherine Sebban, et al.
Bulletin Du Cancer|November 30, 2011
[Anticancer drugs management in renal insufficiency patients]Sarah Zimmer-Rapuch, Stéphanie Lheureux, Fabien Brocard, et al.
Bulletin Du Cancer|December 3, 2011
[Antihormonal therapy in breast cancer and mTOR inhibitors]Pierre-Étienne Heudel, Olivier Tredan, Isabelle Ray-Coquard, et al.
Cancers|November 27, 2021
Maintenance Treatment of Newly Diagnosed Advanced Ovarian Cancer: Time for a Paradigm Shift?Paul DiSilvestro, Nicoletta Colombo, Philipp Harter, et al.
Cancer|February 4, 2009
Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO)Andreas du Bois, Alexander Reuss, Eric Pujade-Lauraine, et al.
Cancer Treatment Reviews|October 25, 2020
Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatmentIsabelle Ray-Coquard, Mansoor Raza Mirza, Sandro Pignata, et al.
Bulletin Du Cancer|February 4, 2006
[News of the year 2005 in sarcomas]Jérôme Fayette, Pierre Méeus, Marie-Pierre Sunyach, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 28, 2023
Evolving treatment paradigms in metastatic or recurrent low-grade endometrial cancer: When is hormonal-based therapy the preferred option?Haider Mahdi, Isabelle Ray-Coquard, Domenica Lorusso, et al.
Pageof 63